Cetuximab for metastatic colorectal cancer.
Garattini
Silvio
S
Torri
Valter
V
Floriani
Irene
I
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D003362:Cost-Benefit Analysis; D018450:Disease Progression; D066246:ErbB Receptors / Q000276:immunology; D011905:Genes, ras; D006801:Humans; D009154:Mutation; D015996:Survival Rate
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D066246:ErbB Receptors; D000068818:Cetuximab